Gilead Sciences | GILD - Current Liabilities

Stock Price
151.40
Daily Change
0.28 0.19%
Monthly
17.26%
Yearly
37.70%
Q1 Forecast
146.71

Gilead Sciences reported $11.81B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Coherus Biosciences USD 372.3M 108.67M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025